Sanofi Q1 2024 Adj EPS $0.97 Beats $0.94 Estimate, Sales $11.364B Beat $11.044B Estimate
Portfolio Pulse from Benzinga Newsdesk
Sanofi (NASDAQ:SNY) reported Q1 2024 adjusted EPS of $0.97, surpassing the $0.94 estimate, and sales of $11.364B, exceeding the $11.044B estimate. This represents a 16.72% decrease in EPS and a 3.58% increase in sales year-over-year.
April 25, 2024 | 5:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi reported a Q1 2024 adjusted EPS of $0.97, beating estimates, and sales of $11.364B, exceeding expectations. EPS saw a 16.72% decrease while sales increased by 3.58% YoY.
Sanofi's earnings and sales beat are likely to positively impact its stock price in the short term. The beat on both top and bottom lines indicates strong financial health and operational efficiency, despite the year-over-year decrease in EPS. The sales growth suggests resilience and potential for future growth, which could boost investor confidence and drive up the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100